From our earliest days, Sanofi Genzyme has recognized that to live up to our commitment to patients, we must take a global approach to our business. Our roots in treating rare genetic diseases made this approach a necessity: because these disorders affect such small numbers, identifying those who need our therapies has always meant reaching out to patients all over the world, regardless of national boundaries.
Over the years as our product portfolio has grown, Sanofi Genzyme has continued to evolve and expand our presence into new regions based on identified patient needs. Our strategy is deliberate and focused: we start by building a local management team that understands regional concerns and practices. These teams work closely with governments and regulatory authorities, health care providers, and insurers to determine how we can best reach patients and bring value to local health care systems. Sanofi Genzyme's extensive international presence also helps us reach patients whose financial or geographic circumstances make access to treatment a challenge, through our various free drug and charitable support programs.
For Sanofi Genzyme, a global presence involves more than worldwide sales and marketing offices. We've located important operational facilities – including R&D labs and manufacturing plants – as well as key business support functions at sites around the world strategically selected for their proximity to scientific innovation centers, regulatory expertise, and other resources.
Our Headquarters: Genzyme Center
Located in Cambridge, Massachusetts, near Sanofi Genzyme’s original Boston home, our environmentally advanced world headquarters opened in 2003 as a highly visible expression of our commitment to innovation, transparency, and collaboration.
Framingham Science Center
Genzyme's Framingham, Massachusetts, campus is home to our largest concentration of employees – approximately 2000 – including those working at our world-class Science Center, the company's hub for early-stage research.
Manufacturing at Geel, Belgium
One of Europe's largest bio-manufacturing sites, Genzyme's state-of-the-art plant in Geel, Belgium, opened in 2005 to expand our global production capabilities in protein-based therapies.
Manufacturing in Waterford, Ireland
Our recently expanded manufacturing facility in Waterford, Ireland provides fill-finish capabilities for several of our products.
Find Genzyme Around the World
See a full list of Genzyme's worldwide locations, with contact information for country and regional offices.
View our Global Locator
While our origins and our headquarters are in the United States, Genzyme now has employees working in 40+ countries to serve patients in 100+ countries. The diverse skills and perspectives of our global workforce are integral to our success and growth, helping us record more than half of our product sales outside the U.S. This global reach has evolved through a series of strategic moves, from acquisitions and partnerships to the establishment of entirely new regional hubs.
Expansion into Europe occurred early in Genzyme's history with the 1982 acquisition of a manufacturing plant in Haverhill, England – years before we began marketing any therapeutic products. In the early 1990s, as we began seeking regulatory approvals for our first protein-based therapies, Western Europe was a logical first market because of its identified patient populations and well-established health care systems. We now have sales offices all over the region, and several key European sites play a critical role in our operations:
- Haverhill was expanded in 2001 to support various product manufacturing and distribution processes
- Our facility in Waterford, Ireland, acquired in 2001, performs fill/finish for many of our products
- In 2005 we opened a plant in Geel, Belgium, to increase production capacity of our protein-based therapies
- We established our first research center outside the U.S. in 2005 in Cambridge, England, joining that city's exceptional scientific community
- A new bio-manufacturing facility opened in 2011 in Lyon, France, to produce therapeutic antibodies
While Asia-Pacific has been largely a more recent expansion, Genzyme’s first foray into business beyond the U.S. and U.K. was actually in Japan: our Tokyo office opened in 1987. In 1996 we became the first foreign company in Japan to gain marketing approval for a drug without a Japanese partner, and the country is now a strong and growing market for several of our products.
After Europe, Latin America became the next major region for Genzyme's expansion. We established an office in Brazil in 1997 as a management hub to oversee operations in the area. Over time we expanded to several more offices in Latin America, and this "hub" approach became a model for the company's growth in new territories around the world.
Arina from St. Petersburg was Genzyme's first Gaucher disease patient in Russia.
In 2001 we opened an office of just two employees in Moscow, Russia, which is now the center of our Eastern European operations. Most recently, we expanded into several emerging markets in Asia-Pacific, including India and China in 2005, as well as established a Middle Eastern hub in Dubai in 2006. As we continue to grow and diversify internationally, our actions continue to be guided by one overriding principle: serving a global patient population.
Last Updated: 6/28/2016